Evidence map›Paper›PMID 39341602›Full record

ArticleJournal of substance use and addiction treatment2024

Health service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage.

Brittany B Dennis, Glenda Babe, Anastasia Gayowsky, Tea Rosic, Myanca Rodrigues, Paxton Bach, Richard Perez, Claire de Oliveira, Jeffrey Samet, Victoria Weaver and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Brittany B DennisBritish Columbia Centre on Substance Use, Vancouver, BC, Canada; Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: brittany.dennis@medportal.ca.
Glenda BabeICES McMaster, McMaster University, Hamilton, Ontario, Canada.
Anastasia GayowskyICES McMaster, McMaster University, Hamilton, Ontario, Canada.
Tea RosicDepartment of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Psychiatry, University of Ottawa, Ontario, Canada.
Myanca RodriguesDepartment of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Paxton BachBritish Columbia Centre on Substance Use, Vancouver, BC, Canada; Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Richard PerezICES McMaster, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Claire de OliveiraInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; ICES, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
Jeffrey SametDepartment of Medicine, Boston University, Boston, USA.
Victoria WeaverDivision of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Samantha YoungBritish Columbia Centre on Substance Use, Vancouver, BC, Canada; Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Joanna DionneDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Aijaz AhmedDepartment of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.
Donghee KimDepartment of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.
Lehana ThabaneDepartment of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada; Biostatistics Unit, Research Institute at St Joseph's Healthcare, Hamilton, Ontario, Canada; Departments of Pediatrics/Anesthesia, McMaster University, Hamilton, Ontario, Canada; Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa.
Zainab SamaanDepartment of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.

Funding

Advancing Clinical Research Training within Addiction Residency ProgramsR25DA033211 · NIDA · BOSTON MEDICAL CENTER · PI Patrick O'Connor, JEFFREY H. SAMET · 2012 to 2026
$4.2M
Mentoring the next generation of addiction clinician scientists while responding to the opioid epidemicR25DA037756 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI FAIRBAIRN, NADIA · 2014 to 2023
$3.6M
NIDA NIH HHS R25 DA033211NIDA NIH HHS R25 DA037756
6 · The paper itself

Abstract

backgroundAmong patients with opioid use disorder (OUD), high rates of overdose and death have been reported in subgroups with Hepatitis C Virus (HCV). Evidence on the comorbid effect of HCV on clinical and substance use trajectories has been limited by small sample sizes, short follow-up, and heavy reliance on administrative data which lacks granularity on important prognostic factors. Additionally, few studies include populations on substance use treatment.

aimTo establish the impact of HCV exposure (antibody positivity) on health care utilization patterns, substance use treatment response, and death in a cohort of patients with OUD on opioid agonist therapy (OAT).

methodsThis multi-center prospective cohort study recruited adult patients with OUD on OAT from 57 substance use treatment centers in Ontario, Canada. The study collected substance use outcomes, and classified patients with ≥50 % positive opioid urine screens over one year of follow-up as having poor treatment response. Additional data obtained via linkage with ICES administrative databases evaluated the relationship between HCV status, healthcare service utilization, and death over 3 years of follow-up. Multiple logistic regression models established the adjusted impact of HCV on various outcomes.

resultsAmong recruited participants (n = 3430), 44.10 % were female with a mean age of 38.64 years (Standard deviation: 10.96). HCV was prevalent in 10.6 % of the cohort (n = 365). Methadone was used most often (83.9 %, n = 2876), followed by sublingual buprenorphine (16.2 %, n = 554). Over the three-year follow-up, 5.3 % of patients died (n = 181). Unadjusted results reveal rates of hospitalization (all-cause, mental-health related, critical care) and emergency department visits (mental health-related), were significantly higher among HCV patients. Associations diminished in adjusted models. Active injection drug use exhibited the highest predictive risk for all outcomes.

conclusionA high degree of acute physical and mental illness and its resulting health service utilization burden is concentrated among patients with OUD and comorbid HCV. Future research should explore the role for targeted interventions and how best to implement integrated healthcare models to better address the complex health needs of HCV populations who inject drugs.

Indexed as

ComorbidityHepatitis COpioid-Related DisordersAdultAnalgesics, OpioidDatabases, FactualDrug OverdoseFemaleHumansMaleMiddle AgedOntarioOpiate Substitution TreatmentPatient Acceptance of Health CareProspective StudiesAnalgesics, OpioidBuprenorphineHepatitis C virusInjection useIntravenous drug use (IVDU)Liver diseaseMedication assisted therapyMethadoneMethadone maintenance treatmentOpioid abuseOpioid addictionOpioid agonist therapyOpioid use disorder

Identifiers

PMID39341602
PMCPMC11750131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.